Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4D | Q08499 | 3/20 | 0.53 |
| ▸ | PDE4B | Q07343 | 3/20 | 0.53 |
| ▸ | PDE4A | P27815 | 2/20 | 0.53 |
| ▸ | PDE4C | Q08493 | 2/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.50 |
| ▸ | KDM1A | O60341 | 1/20 | 0.48 |
| ▸ | TOP2A | P11388 | 1/20 | 0.45 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | NPY2R | P49146 | 1/20 | 0.45 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.43 |
| ▸ | DPP4 | P27487 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13718678 | 0.83 | GPR119 (0.66) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL2277132 | 0.83 | PDE4B (0.64) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL31583988 | 0.83 | PDE4B (0.64) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL18318290 | 0.83 | PDE4B (0.53) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL12801190 | 0.83 | PDE4B (0.53) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL31079299 | 0.82 | BACE1 (0.51) | GPR119DPP4 | |
| SCHEMBL29964426 | 0.81 | GPR119 (0.53) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL16828811 | 0.81 | PDE4B (0.52) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL274655 | 0.81 | PDE4B (0.52) | PDE4DPDE4BPDE4APDE4CGPR119 | |
| SCHEMBL14862778 | 0.81 | GPR119 (0.61) | PDE4DPDE4BPDE4APDE4CGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2024-10-17 | — | — | US | disclosed |
| WO-2022226668-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | ONTARIO INSTITUTE FOR CANCER RESEARCH (OICR) (CA) | 2022-11-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240343704-A1 | HALO-SUBSTITUTED AMINO PYRIDINE COMPOUNDS AS INHIBITORS OF THE HAEMATOPOIETIC PROGENITOR KINASE 1 (HPK1) | CMPK1, WNK1, AAK1 | PDE4D 3794/4885PDE4B 3312/4885PDE4A 2610/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.